INmune Bio Inc (INMB)
INmune Bio Inc. is a clinical-stage immunology company listed on NASDAQ under the ticker INMB. The company is focused on developing therapies designed to reprogram the innate immune system in order to address a range of diseases in the United States. Its pipeline includes programs aimed at hematologic malignancies, solid tumors, and chronic inflammation. Key development candidates include INKmune, which is being studied in Phase 1 for high-risk myelodysplastic syndrome, and INB03, which is in Phase II for breast cancer. The company also develops XPro1595 for Alzheimer’s disease and treatment-resistant depression, as well as CORDstrom, a cell suspension intended for intravenous infusion or injection. INmune Bio was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INMB
|
$1.93
|
-0.6% Downside
|
Fair
|
$7
|
260.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-1.3x
|
2.7x
|
—
|
52.905 M
|
32.259 M
|
2.8%
|
83.2%
|
-9.1
|
—
|
48.6%
|
